S

STAAMP Research | San Antonio, TX

Research site

(Unclaimed)

Location

7711 Louis Pasteur Drive, Suite 406, San Antonio, Texas, United States of America

Site insights

Top conditions

Top treatments

OPN-375

dupiluMAb

Obeldesivir

Omalizumab

Remibrutinib

Remdesivir

Dupilumab

DUPIXENT®

OM-85

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 11 total trials

A Study to Assess the Efficacy and Safety of Daily OM-85 in Young Children With Recurrent Wheezing

This study will assess the efficacy and safety of daily OM-85 treatment compared to placebo in children aged 6 months to 5 years with recurrent wheez...

Enrolling

Wheezing Lower Respiratory Illness

Recurrent Wheezing

Drug: OM-85

Drug: Placebo

Locations recently updated

A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines

This is a Phase 3, parallel group, placebo-controlled, double-blind, confirmatory study in patients with CINDU, with an optional Open-label Extension...

Enrolling

Chronic Inducible Urticaria

Drug: Remibrutinib

Other: Placebo

Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)

Primary Objective:To demonstrate the efficacy of dupilumab in study participants with CSU who remain symptomatic despite the use of H1 antihistamine...

Active, not recruiting

Chronic Spontaneous Urticaria

Drug: non sedating H1-antihistamine

Drug: Dupilumab SAR231893

OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps

This is a 16-Week Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of OPN-375 186 μ...

Enrolling

Bilateral Nasal Polyposis

Drug: OPN-375